MET-097i (fully biased once-monthly GLP-1 RA) VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered class-leading Phase 1 results including 8.4% five-week weight loss and 19-day half-life; 12-week monotherapy data expected in late 2025 MET-233i + MET-097i 12-week co-administration data expected by year-end 2025 or early 2026 Oral peptide programs on track; four-week data for selected lead (MET-097o or ...